Journals / Düzce Tıp Fakültesi Dergisi / 2010 / Cilt: 12 - Sayı: 3

The Relationship Between The Level of Serum Uric Acid and No-Reflow Phenomenon After Primary Percutaneous Coronary Intervention in Patients With St Segment Elevated Myocardial Infarction

St Elevasyonlu Miyokard İnfarktüslü Hastalarda Primer Perkütan Girişim Sonrası No-Reflow Fenomeni Gelişimi ile Serum Ürik Asit Düzeyleri Arasındaki İlişki

Pages
40–44
Publication Date
2010-12-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Patient with myocardial blushgrades 0-1 were accepted as no-reflow group, patients with MBG 2-3 normal perfusion group.When the serum uric acid value of no-reflow and normal perfusion groups was compared, therewas statistificaly significant difference (respectively 6,680±1,11 mg/dl versus 5,066±0,68 mg/dl.p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:No-reflow phenomenon is the absence of myocardial perfusion despite adequate dilatation ofthe infarct related coronary artery during percutaneous coronary intervention.
📊
Key Findings & Data:Therefore uric acid may play reperfusion injury and no-reflow.İn this study, we aimed to compare serum uric acid value of ST segment elevated Mİ patientsgroups whith no-reflow phenomenon and normal miyocardial perfusion after primary coronaryintervention.47 patients was enrolled consecutively to this study.
💡
Conclusion & Impact:Patient with myocardial blushgrades 0-1 were accepted as no-reflow group, patients with MBG 2-3 normal perfusion group.When the serum uric acid value of no-reflow and normal perfusion groups was compared, therewas statistificaly significant difference (respectively 6,680±1,11 mg/dl versus 5,066±0,68 mg/dl.p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:No-reflow · Ürik asit · Akut miyokard infarktüsü

Abstract

No-reflow phenomenon is the absence of myocardial perfusion despite adequate dilatation ofthe infarct related coronary artery during percutaneous coronary intervention. Uric acid (UA)release during ischemia and washout from the ischemic zone during reperfusion is adeninenucleotide breakdown product. Therefore uric acid may play reperfusion injury and no-reflow.İn this study, we aimed to compare serum uric acid value of ST segment elevated Mİ patientsgroups whith no-reflow phenomenon and normal miyocardial perfusion after primary coronaryintervention.47 patients was enrolled consecutively to this study. During hospital admission, patients bloodsamples were taken for serum uric acid value. Patients was grouped as no reflow and normalperfusion groups according to myocardial blush grades (MBG). Patient with myocardial blushgrades 0-1 were accepted as no-reflow group, patients with MBG 2-3 normal perfusion group.When the serum uric acid value of no-reflow and normal perfusion groups was compared, therewas statistificaly significant difference (respectively 6,680±1,11 mg/dl versus 5,066±0,68 mg/dl.p

Özet

Perkütan koroner girişimlerde, sorumlu arterin açılmasına rağmen, miyokardial perfüzyonunsağlanamaması “no-reflow” fenomeni olarak tanımlanır. Adenin nükleotit metabolitlerinden biriolan ürik asidin hem iskemi sırasında, hem de reperfüzyon sırasında iskemik dokulardansalındığı gösterilmiş ve iskemik hasar ile reperfüzyon hasarında rol oynayabileceğidüşünülmüştür. Biz çalışmamızda ST elevasyonlu akut miyokard infarktüsü tanısı alıp, primerperkütan girişim uygulanan hastalarımızda, işlem sonrası anjiyografik olarak no-reflowfenomeni gelişen ve gelişmeyen gruplarda ürik asit değerlerini karşılaştırdık. Çalışmaya 47 hasta alındı. Olguların hastaneye gelişinde kan örnekleri alınarak ürik asit sayımıyapıldı. Hastalar primer perkütan girişim sonrası Miyokardial Blush Grade (MBG) derecelerinegöre iki gruba ayrıldı. Buna göre MBG 0 ve 1 olan olgular no-reflow fenomeni var, MBG 2 ve3 olan olgular no-reflow fenomeni yok, olarak kabul edildi.İki grup mutlak ürik asit değerleri açısından karşılaştırıldı ve no-reflow fenomeni gözlenenhastaların ürik asit değerleri ortalaması 6,680±1,11 mg/dl iken, no-reflow gözlenmeyen grupta5,066±0,68 mg/dl idi. İki değer arasındaki fark istatistiksel olarak anlamlı kabul edildi.(p

🔖

Cite This Article

ERDEN, E. Ç., SÖZEN, S. B., KAYAPINAR, O., ÇAĞLAR, S. O., BAŞAR, C., ERDEN, İ. (2010). The Relationship Between The Level of Serum Uric Acid and No-Reflow Phenomenon After Primary Percutaneous Coronary Intervention in Patients With St Segment Elevated Myocardial Infarction. Düzce Tıp Fakültesi Dergisi, Cilt: 12 - Sayı: 3, 40–44. https://ajindex.com/articles/420256

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Swain J, Gutteridge JMC.Prooxidant iron and copper, with ferroxidase and xanthine oxidase activities in human atherosiclerosis material. FEBS Lett. 368:513-515, 1995. Ross R. The pathogenesis of atherosclerosis-an update. N Engl J Med. 314:488-500, 1986.
  2. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med. 328: 673-9, 1993. The GUSTO angiographic investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary- artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 329: 1615-22, 1993.
  3. Morishima I, Sone T, Mokuno S, et al. Clinical significance of no-reflow phenomenon observed on angiography after successful treatment of acute myocardial infarction with percutaneous transluminal coronary angioplasty. Am Heart J. 130: 239-43, 1995.
  4. Piana RN, Paik GY, Moscucci M, et al. Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. Circulation. 89: 2514-8, 1994.
  5. Hamada S, Nakamura S, Sugiura T, et al. Early detection of the no-reflow phenomenon in reperfused acute myocardial infarction using technetium-99m tetrofosmin imaging. Eur J Nucl Med. 26: 208-14, 1999.
  6. Ragosta M, Camarano G, Kaul S, et al. Microvascular integrity indicates myocellular viability in patients with recent myocardial infarction. New insights using myocardial contrast echocardiography. Circulation. 89: 2562-9, 1994.
  7. Van't Hof A.W.J., Liem A., Suryapranta H.: Angiographic Assessment of Myocardial Reperfusion in patients treated with primary coronary angioplasty for acute myocardial infarction. Myocardial blush grade. Circulation. 97, 2302-2306, 1998.
  8. Kuzmin AI, Tskitishvili OV, Serebryakova LI, Kapelko VI, Majorova IV, Medvedev OS. Allopurinol: kinetics, inhibition of xanthine oxidase activity, and protective effect in ischemic- reperfused canine heart as studied by cardiac microdialysis. J Cardiovasc Pharmacol. 25(4):564-71, 1995.
  9. DeWall RA, Vasko KA, Stanley EL, Kezdi P. Responses of the ischemic myocardium to allopurinol. Am Heart J. 82:362-370, 1971.
  10. Bando K, Tago M, Teramoto S. Prevention of free radical- induced myocardial injury by allopurinol. Experimental study in cardiac preservation and transplantation. J Thorac Cardiovasc Surg. 95:465-473, 1988.
  11. Gertler MM, Garn SM, Levine SM. Serum uric acid in relation to age and physique in health and in coronary heart disease. Ann Intern Med. 34:1421-1431.